Exhaled breath drug detection using differential mobility spectrometry

项目摘要 这项提议寻求扩展呼吸分析技术，该技术正在作为NIH的重点积极研究 授予#6R42DA049655-02并利用此技术进行新冠肺炎快速诊断。有一个迫切的需求 用于对新冠肺炎进行敏感和特异的诊断测试，这些测试可以快速进行。差异化机动性 可能采用目前正在研究的用于毒品检测的光谱分析(DMS)呼气分析技术 来填补这一空白。 在本补充期间，我们将进行生物标记物的发现工作，以确定呼气分子。 最适合用作新冠肺炎生物标志物的物种。一旦确定了目标物种，方法 将调查可以在管理新冠肺炎测试的安全范式内实施的捕获。 我们还将启动与FDA的对话，并制定FDA的批准战略，以加快部署 基于这项正在研究的技术的未来基于呼吸的新冠肺炎诊断仪 行政补助金的家长拨款。

Project Summary This proposal seeks to expand upon breath analysis technology that is being actively studied as the focus of NIH grant #6R42DA049655-02 and leverage this technology for rapid COVID-19 diagnostics. There is a dire need for sensitive and specific diagnostic tests for COVID-19 that can be performed quickly. The differential mobility spectrometry (DMS) breath analysis technology currently under investigation for drug detection may be adapted to fill this void. During this supplement we will perform a biomarker discovery effort to determine the exhaled breath molecular species most suitable for use as a COVID-19 biomarker. Once a target species has been identified, methods of capture that can be implemented within the safety paradigm governing COVID-19 testing will be investigated. We will also initiate conversation with the FDA and develop an FDA approval strategy to expedite the deployment of a future breath based COVID-19 diagnostic instrument based upon the technology being studied under this administrative supplement’s parent grant.